Haleon PLC (HLN) Stock AnalysisHLNStock AnalysisHaleon PLC

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and others. The Company's segments include North America, Europe, Asia Pacific, and International. Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban. It operates in the Healthcare sector (PERFUMES, COSMETICS, AND OTHER TOILET PREPARATIONS industry).

Haleon PLC is a good buy right now due to its current price of 10.11, which is near its 20-day simple moving average of 9.922, indicating a bullish trend. The RSI is at 61.389, suggesting that the stock is neither overbought nor oversold, providing a favorable entry point. Additionally, the gross margin stands at a strong 62.88%, reflecting solid profitability. However, the main risk is the debt to equity ratio, which is at 53.00%, indicating a moderate level of financial leverage that could impact future performance.